ITGAV

From Wikipedia, the free encyclopedia
Jump to: navigation, search
ITGAV
PDB 1jv2 EBI.jpg
Available structures
PDB Ortholog search: PDBe RCSB
Identifiers
Aliases ITGAV, CD51, MSK8, VNRA, VTNR, integrin subunit alpha V
External IDs MGI: 96608 HomoloGene: 20510 GeneCards: 3685
RNA expression pattern
PBB GE ITGAV 202351 at tn.png
More reference expression data
Orthologs
Species Human Mouse
Entrez
Ensembl
UniProt
RefSeq (mRNA)

NM_001144999
NM_001145000
NM_002210

NM_008402

RefSeq (protein)

NP_001138471.1
NP_001138472.1
NP_002201.1

NP_032428.2

Location (UCSC) Chr 2: 186.59 – 186.68 Mb Chr 2: 83.72 – 83.81 Mb
PubMed search [1] [2]
Wikidata
View/Edit Human View/Edit Mouse

Integrin alpha-V is a protein that in humans is encoded by the ITGAV gene.[3]

ITAGV encodes integrin alpha chain V. Integrins are heterodimeric integral membrane proteins composed of an alpha chain and a beta chain. Alpha V undergoes post-translational cleavage to yield disulfide-linked heavy and light chains, that combine with multiple integrin beta chains to form different integrins. Among the known associating beta chains (beta chains 1,3,5,6, and 8; 'ITGB1', 'ITGB3', 'ITGB5', 'ITGB6', and 'ITGB8'), each can interact with extracellular matrix ligands; the alpha V beta 3 integrin, perhaps the most studied of these, is referred to as the Vitronectin receptor (VNR). In addition to adhesion, many integrins are known to facilitate signal transduction.[4]

Alpha V class integrins[edit]

In mammals the integrins that include alpha-V are :

Name Synonyms Distribution Ligands
αVβ1 ocular melanoma; neurological tumors vitronectin; fibrinogen
αVβ3 vitronectin receptor[5] activated endothelial cells, melanoma, glioblastoma vitronectin,[5] fibronectin, fibrinogen, osteopontin, Cyr61
αVβ5 widespread, esp. fibroblasts, epithelial cells vitronectin and adenovirus
αVβ6 proliferating epithelia, esp. lung and mammary gland fibronectin; TGFβ1+3
αVβ8 neural tissue; peripheral nerve fibronectin; TGFβ1+3

As a drug target[edit]

The mAbs intetumumab, and abituzumab target this protein which is found on some tumour cells.[6]

See also[edit]

References[edit]

  1. ^ "Human PubMed Reference:". 
  2. ^ "Mouse PubMed Reference:". 
  3. ^ Sosnoski DM, Emanuel BS, Hawkins AL, van Tuinen P, Ledbetter DH, Nussbaum RL, Kaos FT, Schwartz E, Phillips D, Bennett JS, et al. (Aug 1988). "Chromosomal localization of the genes for the vitronectin and fibronectin receptors alpha subunits and for platelet glycoproteins IIb and IIIa". J Clin Invest. 81 (6): 1993–8. doi:10.1172/JCI113548. PMC 442653free to read. PMID 2454952. 
  4. ^ "Entrez Gene: ITGAV integrin, alpha V (vitronectin receptor, alpha polypeptide, antigen CD51)". 
  5. ^ a b Hermann P, Armant M, Brown E, Rubio M, Ishihara H, Ulrich D, Caspary RG, Lindberg FP, Armitage R, Maliszewski C, Delespesse G, Sarfati M (February 1999). "The vitronectin receptor and its associated CD47 molecule mediates proinflammatory cytokine synthesis in human monocytes by interaction with soluble CD23". J. Cell Biol. 144 (4): 767–75. doi:10.1083/jcb.144.4.767. PMC 2132927free to read. PMID 10037797. 
  6. ^ Élez, E.; Kocáková, I.; Höhler, T.; Martens, U. M.; Bokemeyer, C.; Van Cutsem, E.; Melichar, B.; Smakal, M.; Csőszi, T.; Topuzov, E.; Orlova, R.; Tjulandin, S.; Rivera, F.; Straub, J.; Bruns, R.; Quaratino, S.; Tabernero, J. (2015). "Abituzumab combined with cetuximab plus irinotecan versus cetuximab plus irinotecan alone for patients withKRASwild-type metastatic colorectal cancer: the randomised phase I/II POSEIDON trial". Annals of Oncology. 26 (1): 132–140. doi:10.1093/annonc/mdu474. ISSN 0923-7534. 

Further reading[edit]

External links[edit]